The clinical success of the taxanes and the vinca alkaloids has sparked a major search for new drugs that perturb mitotic spindle microtubule dynamics and function, yielding a large number of promising compounds. A potential valuable strategy would be to use core microtubule-targeted drugs along with novel targeted drug therapies as they are developed, where the antitumor activity of a targeted drug can be combined with the power of low dose microtubule-targeted therapy. The goal of such combination therapy is to achieve high efficacy, reduced toxicity, and reduced emergence of drug resistance.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: